SCHEMBL29973456

SCHEMBL29973456

C=C(Cc1nc(C2(c3ccc(C(F)(F)F)c(Cl)c3)CC2)no1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 1/20 0.36
▸ OPRM1 P35372 3/20 0.33
▸ S1PR1 P21453 2/20 0.33
▸ KMO O15229 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ NOTUM Q6P988 1/20 0.32
▸ PDE2A O00408 3/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ MRGPRX4 Q96LA9 1/20 0.31
▸ OPRL1 P41146 2/20 0.31
▸ SCN1A P35498 1/20 0.31
▸ SCN2A Q99250 1/20 0.31
▸ SCN3A Q9NY46 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23588223 1.00 CNR2 (0.36) CNR2OPRM1S1PR1KMOMEN1
SCHEMBL23578132 0.85 KMT2A (0.39) OPRM1MEN1KMT2AHTTALDH1A1
SCHEMBL29844081 0.85 SLC6A3 (0.34) MEN1KMT2AHTTPDE2ASLC6A2
SCHEMBL23578140 0.85 SLC6A3 (0.34) MEN1KMT2AHTTPDE2ASLC6A2
SCHEMBL23588358 0.85 MEN1 (0.34) MEN1KMT2AHTTALDH1A1L3MBTL1
SCHEMBL23588170 0.83 RORC (0.32) MEN1KMT2AHTT
SCHEMBL23578231 0.83 MEN1 (0.37) MEN1KMT2AHTTPDE2AALDH1A1
SCHEMBL23578288 0.82 MAPT (0.37) S1PR1MEN1KMT2AHTTALDH1A1
SCHEMBL23578427 0.82 KMT2A (0.39) MEN1KMT2AHTTALDH1A1TSHR
SCHEMBL23578426 0.81 MEN1 (0.32) MEN1KMT2AHTTALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 CNR2 275/4885OPRM1 3277/4885S1PR1 2590/4885
US-12617762-B2 Carboxy derivatives with antiinflamatory properties CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CNR2 71/4885OPRM1 219/4885S1PR1 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback